Cerebral Venous Sinus Thrombosis in Patients With COVID-19 Cerebral Venous Sinus Thrombosis in Patients With COVID-19
While cerebral venous sinus thrombosis is rare in the non-COVID general population, this study found a high incidence in patients hospitalized with COVID-19.Stroke (Source: Medscape Critical Care Headlines)
Source: Medscape Critical Care Headlines - September 27, 2022 Category: Intensive Care Tags: Neurology & Neurosurgery Journal Article Source Type: news

The TAVR Subclinical Leaflet Thrombosis Puzzle The TAVR Subclinical Leaflet Thrombosis Puzzle
Two recent studies address some important missing aspects of the puzzle of subclinical leaflet thrombosis, which is present in up to 10% to 15% of patients after TAVR---but questions still remain.Circulation (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - September 26, 2022 Category: Consumer Health News Tags: Cardiology Journal Article Source Type: news

Blood clot warning: Five foods that could ‘keep blood from moving’ - ‘steer clear’
Foods that contribute to a build-up of plaque in the arteries may also predispose the body to other diseases through inflammation, researchers warn. These, in time, could start interfering with the body's blood clotting mechanisms and pave the way to deep vein thrombosis. (Source: Daily Express - Health)
Source: Daily Express - Health - September 17, 2022 Category: Consumer Health News Source Type: news

Prevalence of cerebral sinovenous thrombosis in abusive head trauma - Burtard C, Panks J, Silverman LB, Lindberg DM, Stence NV, Neuberger I, Maloney J, White C, Mirsky DM.
The objective of this study was to determine the prevalence of CSVT and subdural hemorrhage (SD... (Source: SafetyLit)
Source: SafetyLit - September 13, 2022 Category: International Medicine & Public Health Tags: Age: Adolescents Source Type: news

Evolution of platelet activation parameters during septic shock in intensive care unit
During severe sepsis, platelet activation may induce disseminate microvascular thrombosis, which play a key role in critical organ failure. Crucially, most of the studies in this field have explored platelet-leukocyte interactions in animal models, or explored platelets under the spectrum of thrombocytopenia or disseminated intravascular coagulation and have not taken into account the complex interplay that might exist between platelets and leukocytes during human septic shock nor the kinetics of platelet activation. Here, we assessed platelet activation parameters at the admission of patients with sepsis to the intensive ...
Source: Current Awareness Service for Health (CASH) - September 5, 2022 Category: Consumer Health News Source Type: news

What Causes Sudden Vision Loss?
Discussion Vision loss, whether chronic or acute, is distressing at any time for patients and families. Prompt evaluation and treatment are important as maintenance of any acuity and light or movement is considered paramount. Most vision loss is due to chronic problems and aging issues but the differential diagnosis is broad. For any age, but especially children, uncorrected refractive errors can cause problems in not only in childhood but throughout someone’s lifetime. Visual impairment for distance vision is considered mild if worse than 6/12 in meters = 20/40 in feet or 0.3 LogMAR and for moderate impairment is 6/...
Source: PediatricEducation.org - September 5, 2022 Category: Pediatrics Authors: Pediatric Education Tags: Uncategorized Source Type: news

Case report of a 13-year-old female with trauma secondary to a fall from a golf cart, found to have intraparenchymal & subarachnoid hemorrhages with transverse sinus thrombosis - Donato UMJ, Donato S, Galligan A.
Cerebral venous sinus thrombosis (CVST) is the occlusion of cerebral veins of the brain secondary to blood clot formation. These can result in increased intracranial pressure, cerebral edema, and may even have fatal consequences such as a stroke. Despite C... (Source: SafetyLit)
Source: SafetyLit - September 3, 2022 Category: International Medicine & Public Health Tags: Age: Adolescents Source Type: news

Stronger Antiplatelet Better for VTE Prophylaxis After Joint Replacement
(MedPage Today) -- Enoxaparin bested aspirin for preventing symptomatic venous thromboembolism (VTE) after total hip or total knee arthroplasty when used without initial anticoagulation in the CRISTAL randomized trial. These events occurred within... (Source: MedPage Today Cardiovascular)
Source: MedPage Today Cardiovascular - August 23, 2022 Category: Cardiology Source Type: news

Blood Biomarker Linked to Incident VTE in COVID-19 Patients
MONDAY, Aug. 22, 2022 -- Higher levels of soluble urokinase plasminogen activator receptor (suPAR) are associated with incident venous thromboembolism (VTE) among patients hospitalized for COVID-19, regardless of D-dimer levels, according to a study... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - August 22, 2022 Category: Pharmaceuticals Source Type: news

VTE Risk Substantially Lower in Breakthrough COVID Cases
(MedPage Today) -- While mild COVID-19 increases venous thromboembolism (VTE) risk, those events are much less likely for vaccinated than unvaccinated patients, a large population-based study showed. COVID-19 overall raised 30-day risk of deep... (Source: MedPage Today Cardiovascular)
Source: MedPage Today Cardiovascular - August 19, 2022 Category: Cardiology Source Type: news

Updates on Treatment/Prevention of VTE in Cancer Patients Updates on Treatment/Prevention of VTE in Cancer Patients
Updated clinical practice guidelines for the treatment and prevention of venous thromboembolism (VTE) for patients with cancer now include a section on patients who also have COVID-19.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - August 8, 2022 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news

Chrono-pharmacology-based Antiplatelet Therapy for Acute MI Chrono-pharmacology-based Antiplatelet Therapy for Acute MI
A new study uncovered a circadian rhythm in nuclear receptor gene expression in platelets, revealing the importance of circadian rhythmicity in platelet activation and thrombus formation.European Heart Journal (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - July 26, 2022 Category: Consumer Health News Tags: Cardiology Journal Article Source Type: news

SVT as a Possible Consequence of ChAdOx1 nCoV-19 Vaccine SVT as a Possible Consequence of ChAdOx1 nCoV-19 Vaccine
This report suggests that superficial venous thrombosis may be an addition to the list of adverse events associated with ChAdOx1 nCoV-19 (Covishield) vaccine.Journal of Medical Case Reports (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - July 14, 2022 Category: Consumer Health News Tags: Family Medicine/Primary Care Journal Article Source Type: news

New data from phase III HAVEN 6 study reinforce favourable safety and efficacy profile of Roche ’s Hemlibra in people with moderate or mild haemophilia A
Hemlibra continues to demonstrate clinically meaningful bleed control, with 66.7% of participants with moderate or mildhaemophilia A experiencing zero treated bleeds at 55.6 weeks median follow-up [1]New data also reinforceHemlibra ’sfavourable safety profile, with no new safety signals observed [1]There is limited information and treatment guidance on moderate and mildhaemophilia A, which can lead to delayed or missed diagnoses of bleeding episodes [2]Hemlibra is approved to treat people of all ages withhaemophilia A with factor VIII inhibitors in more than 110 countries and for people of all ages without factor VIII in...
Source: Roche Media News - July 11, 2022 Category: Pharmaceuticals Source Type: news

Anthos Therapeutics Announces that Abelacimab has Received FDA Fast Track Designation for the Treatment of Thrombosis Associated with Cancer
Abelacimab is a dual-acting fully human monoclonal antibody targeting both Factor XI and Factor XIa with high affinity and selectivity Earlier this year abelacimab became the first-ever Factor XI inhibitor to begin enrolling patients in a Phase 3 trial ... Biopharmaceuticals, FDA Anthos Therapeutics, abelacimab, Factor XI inhibitor, thrombosis (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - July 11, 2022 Category: Pharmaceuticals Source Type: news